...
首页> 外文期刊>Journal of Medical Virology >High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy
【24h】

High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy

机译:尽管进行了预防性治疗,但在实体器官移植后仍存在巨细胞病毒感染的高风险

获取原文
获取原文并翻译 | 示例

摘要

Cytomegalovirus infection (CMV) in solid organ transplant recipients is a major clinical problem. The aim of this study was to evaluate the incidence of CMV infection and its association with mortality during the first year after transplantation in a large solid organ transplant cohort at the Royal Infirmary of Edinburgh between January 2006 and April 2009. Data including the use of CMV prophylaxis, nature of CMV disease, treatment and deceased date (when appropriate) was collected retrospectively using hospital databases and patient notes for all transplanted patients with detectable CMV viraemia. The outcomes between recipients of kidney and liver transplants in the four CMV donor/recipient serostatus categories (D+R+, D-R-, D+R-, D-R+) were compared. A total of 428 individuals were included. Despite the administration of valganciclovir prophylaxis, CMV disease (syndrome or end-organ involvement) was diagnosed within the year of transplantation in the D+R--group in 31.3% of liver and 19.2% of kidney recipients. All D+R- transplant recipients that received CMV-prophylaxis presented with late-onset CMV disease. Furthermore, the rate of CMV disease in the D+R+-group was markedly higher in renal graft recipients compared to liver recipients (22% vs. 5%). The highest mortality was observed among the D+R+ liver and kidney graft recipients with CMV infection. The high incidence of late-onset CMV disease in D+R- transplant recipients receiving CMV prophylaxis demonstrates that CMV disease remains an important problem after organ transplantation. Furthermore, the surprisingly high mortality in the D+R+-transplant patients with CMV viraemia highlights the need for proactive monitoring of this group. J. Med. Virol. 85:893-898, 2013. ? 2013 Wiley Periodicals, Inc.
机译:实体器官移植受者的巨细胞病毒感染(CMV)是主要的临床问题。这项研究的目的是评估2006年1月至2009年4月间在爱丁堡皇家医院的大型实体器官移植队列中,CMV感染的发生率及其与死亡率的关系。数据包括CMV的使用使用医院数据库和患者注释对所有可检测到的CMV病毒血症的移植患者进行回顾性收集预防,CMV疾病的性质,治疗和死亡日期(适当时)。比较了四种CMV供体/受体血清状况类别(D + R +,D-R-,D + R-,D-R +)中肾脏和肝脏移植受者之间的结局。总共包括428个人。尽管已进行了缬更昔洛韦的预防,但在D + R--组移植的当年内,仍在31.3%的肝脏和19.2%的肾脏接受者中诊断出CMV疾病(综合征或终末器官受累)。所有接受CMV预防的D + R-移植患者均出现迟发性CMV疾病。此外,与肝脏患者相比,D + R +-组中CMV疾病的发生率在肾移植患者中明显更高(22%对5%)。在患有CMV感染的D + R +肝肾移植患者中观察到最高的死亡率。在接受CMV预防的D + R移植接受者中,迟发性CMV疾病高发表明,CMV疾病仍然是器官移植后的重要问题。此外,在D + R +移植的CMV病毒血症患者中,出乎意料的高死亡率突出了对这一人群进行积极监测的必要性。 J. Med。病毒。 85:893-898,2013。 2013 Wiley期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号